Salarius Pharmaceuticals Ownership
| SLRX Stock | USD 1.37 0.09 6.16% |
Shares in Circulation | First Issued 2014-06-30 | Previous Quarter 600.4 K | Current Value 1.3 M | Avarage Shares Outstanding 797.1 K | Quarterly Volatility 1.1 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Salarius |
Salarius Stock Ownership Analysis
The company has price-to-book ratio of 0.68. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Salarius Pharmaceuticals recorded a loss per share of 5.14. The entity last dividend was issued on the 22nd of July 2019. The firm had 1:8 split on the 17th of June 2024. Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. Salarius Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 16 people. To find out more about Salarius Pharmaceuticals contact David MBA at 832 834 9144 or learn more at https://www.salariuspharma.com.Besides selling stocks to institutional investors, Salarius Pharmaceuticals also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Salarius Pharmaceuticals' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Salarius Pharmaceuticals' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Salarius Pharmaceuticals Quarterly Liabilities And Stockholders Equity |
|
Roughly 3.0% of Salarius Pharmaceuticals are currently held by insiders. Unlike Salarius Pharmaceuticals' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Salarius Pharmaceuticals' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Salarius Pharmaceuticals' insider trades
Salarius Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Salarius Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Salarius Pharmaceuticals backward and forwards among themselves. Salarius Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Salarius Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Vanguard Group Inc | 2024-06-30 | 0.0 | Geode Capital Management, Llc | 2024-06-30 | 0.0 | Armistice Capital, Llc | 2024-06-30 | 22.8 K | Tower Research Capital Llc | 2024-06-30 | 3.2 K | Ubs Group Ag | 2024-06-30 | 113 | Advisor Group Holdings, Inc. | 2024-06-30 | 53.0 | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 14.0 | Bank Of America Corp | 2024-06-30 | 6.0 | Wells Fargo & Co | 2024-06-30 | 1.0 | Blackrock Inc | 2024-06-30 | 1.0 | Horizon Asset Management Inc/ny | 2024-06-30 | 0.0 |
Salarius Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Salarius Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Salarius Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Salarius Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Rosenblum Mark J over three weeks ago Acquisition by Rosenblum Mark J of 6432 shares of Salarius Pharmaceuticals subject to Rule 16b-3 | ||
Lieber Jonathan I over three months ago Acquisition by Lieber Jonathan I of 1440 shares of Salarius Pharmaceuticals subject to Rule 16b-3 | ||
Rosenblum Mark J over six months ago Acquisition by Rosenblum Mark J of 28000 shares of Salarius Pharmaceuticals at 0.18 subject to Rule 16b-3 | ||
David Arthur over six months ago Acquisition by David Arthur of 20500 shares of Salarius Pharmaceuticals at 0.51 subject to Rule 16b-3 | ||
Hanish Arnold C over six months ago Acquisition by Hanish Arnold C of 20500 shares of Salarius Pharmaceuticals at 0.5711 subject to Rule 16b-3 | ||
Hanish Arnold C over six months ago Acquisition by Hanish Arnold C of 20500 shares of Salarius Pharmaceuticals at 0.5711 subject to Rule 16b-3 |
Salarius Pharmaceuticals Outstanding Bonds
Salarius Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Salarius Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Salarius bonds can be classified according to their maturity, which is the date when Salarius Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Salarius Stock Analysis
When running Salarius Pharmaceuticals' price analysis, check to measure Salarius Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Salarius Pharmaceuticals is operating at the current time. Most of Salarius Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Salarius Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Salarius Pharmaceuticals' price. Additionally, you may evaluate how the addition of Salarius Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.